b.y. Quantitative Medicine Limited

we are the first company to establish a quantitative biochemistry platform for the analysis of genes interaction. our self-developed deep learning service model provides a comprehensive and structural strategy to determine the gene co-expression network of cancers and other diseases related to nucleophosmin (npm1/b23). this model provides important data for health assessment, disease diagnosis, prognosis, and treatment, and for related drug development. our focus has been on cancer-related research and we have successfully obtained important quantitative medical data such as ovarian cancer, breast cancer, pancreatic cancer, liver cancer (viral infection), colorectal cancer, lung cancer and other related cancer recurrence prediction, cancer stage assessment, chemoresistance, metastasis, and distinguishing low-risk and high-risk patients etc. (specificity and prediction accuracy up to 100%) our artificial intelligence deep learning service model has sufficient scalability and can b